Autres langues Valneva

Actions

VLA

FR0004056851

Recherche biotechnologique et médicale

PEA

PEA/PME

Marché Fermé - Euronext Paris Autres places de cotation 17:35:12 16/05/2025			Varia. 5j.	Varia. 1 janv.
2,870 ^EUR	+2,43 %		+1,41 %	+32,75 %

12/05	CAC40 : porté par l'apaisement des tensions USA/Chine	CF
12/05	Valneva SE fournit une mise à jour sur l'utilisation recommandée d'IXCHIQ® chez les personnes âgées aux États-Unis	CI

Autres langues

Valneva : Disclaimer	15/05
Valneva SE Provides Update on Recommended Use of IXCHIQ®? by Elderly Individuals in the United States	12/05
Valneva: Ixchiq suspended in elderly patients by FDA	12/05
FDA And CDC Recommend Pause In Use Of Valneva's Chikungunya Vaccine In Elderly	12/05
US Recommends Pause in Valneva's Chikungunya Vaccine Use	12/05
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States	12/05
French and Benelux stocks-Factors to watch	08/05
Valneva SE Provides Update Following European Medicines Agency Announcement on Use of Ixchiq®? in Elderly	07/05
Europe reviews Valneva's chikungunya vaccine after reports of serious side effects	07/05
Valneva Continues To See Positive Risk-Benefit In Majority Of People With Potential Exposure To Disease	07/05
Europe reviews Valneva's chikungunya vaccine after reports of serious side effects	07/05
Valneva: EMA reviews Ixchiq after serious cases	07/05
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly	07/05
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly	07/05
EMA Starts Review Of Ixchiq Following Reports Of Serious Adverse Events In Elderly People	07/05
Europa revisa vacuna de Valneva contra el chikungunya tras informes de efectos secundarios graves	07/05
Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people	07/05
Valneva SE Reports Earnings Results for the First Quarter Ended March 31, 2025	07/05
Valneva : Q1 2025 Financial Results	07/05
Valneva : Q1 2025 Financial Statements	07/05
Valneva : Company Presentation (May 2025)	07/05
Valneva: E9m net loss in Q1	07/05
French and Benelux stocks-Factors to watch	07/05
Valneva Q1 Revenue EUR 49.2 Million	07/05
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates	07/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Valneva

Actions

VLA

FR0004056851

Recherche biotechnologique et médicale

PEA

PEA/PME

Autres langues

Filtres